| 袁琼婧,谢艳云,王晋伟,彭张哲,余攀,孟婷,黄玲,王维,李晓照,黄韩薇,王芳,高碧霞,赵明辉,周巧玲,张路霞,许辉,中国慢性肾脏病队列研究团队.尿钙排泄量与慢性肾脏病严重程度及预后的相关性研究[J].Chinese journal of Epidemiology,2025,46(2):264-272 |
| 尿钙排泄量与慢性肾脏病严重程度及预后的相关性研究 |
| Study on the correlation between urinary calcium levels and severity and prognosis of chronic kidney disease |
| Received:July 08, 2024 |
| DOI：10.3760/cma.j.cn112338-20240708-00407 |
| KeyWord: 慢性肾脏病 尿钙排泄 终末期肾脏病 全因死亡 心血管疾病 |
| English Key Word: Chronic kidney disease Urinary calcium excretion End-stage kidney disease All-cause mortality Cardiovascular events |
| FundProject:国家重点研发计划（2020YFC2005003）；国家自然科学基金（72125009，91846101，81771938，81900665，82003529，82090021，82270730）；国家科技创新2030计划（2018AAA0102100）；北京大学医学部-密西根大学医学院转化医学与临床研究联合研究（BMU2018JI012，BMU2019JI005）；中国医学科学院医学科学创新基金（2019-I2M-5-046）；北大-百度基金（2019BD017，2020BD004，2020BD005）；湖南省自然科学基金（2020JJ5942，2020JJ4917，2021JJ41039）；湘财教指（〔2022〕44号） |
| Author Name | Affiliation | E-mail | | Yuan Qiongjing | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China
National International Joint Research Center for Medical Metabolomics, Changsha 410008, China
National Clinical Medical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, Changsha 410008, China | | | Xie Yanyun | Organ Fibrosis Key Laboratory of Hunan Province, Central South University, Changsha 410008, China | | | Wang Jinwei | Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China
Department of Nephrology, Peking University, Beijing 100034, China
Key Laboratory of Renal Disease, National Health Commission, Beijing 100034, China
Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing 100034, China
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing 100034, China | | | Peng Zhangzhe | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China
National International Joint Research Center for Medical Metabolomics, Changsha 410008, China
National Clinical Medical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
Organ Fibrosis Key Laboratory of Hunan Province, Central South University, Changsha 410008, China | | | Yu Pan | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China
National International Joint Research Center for Medical Metabolomics, Changsha 410008, China
National Clinical Medical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
Organ Fibrosis Key Laboratory of Hunan Province, Central South University, Changsha 410008, China | | | Meng Ting | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China | | | Huang Ling | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China
National International Joint Research Center for Medical Metabolomics, Changsha 410008, China
National Clinical Medical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
Organ Fibrosis Key Laboratory of Hunan Province, Central South University, Changsha 410008, China | | | Wang Wei | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China
National International Joint Research Center for Medical Metabolomics, Changsha 410008, China
National Clinical Medical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
Organ Fibrosis Key Laboratory of Hunan Province, Central South University, Changsha 410008, China | | | Li Xiaozhao | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China | | | Huang Hanwei | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China
National International Joint Research Center for Medical Metabolomics, Changsha 410008, China
National Clinical Medical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
Organ Fibrosis Key Laboratory of Hunan Province, Central South University, Changsha 410008, China | | | Wang Fang | Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China
Department of Nephrology, Peking University, Beijing 100034, China
Key Laboratory of Renal Disease, National Health Commission, Beijing 100034, China
Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing 100034, China
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing 100034, China | | | Gao Bixia | Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China
Department of Nephrology, Peking University, Beijing 100034, China
Key Laboratory of Renal Disease, National Health Commission, Beijing 100034, China
Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing 100034, China
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing 100034, China | | | Zhao Minghui | Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China
Department of Nephrology, Peking University, Beijing 100034, China
Key Laboratory of Renal Disease, National Health Commission, Beijing 100034, China
Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing 100034, China
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing 100034, China
Peking-Tsinghua Center for Life Sciences, Beijing 100084, China | | | Zhou Qiaoling | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China | | | Zhang Luxia | Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China
Department of Nephrology, Peking University, Beijing 100034, China
Key Laboratory of Renal Disease, National Health Commission, Beijing 100034, China
Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing 100034, China
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing 100034, China
National Institute of Health Data Science at Peking University, Beijing 100871, China | luxia_zhang@163.com | | Xu Hui | Department of Nephrology, Xiangya Hospital of Central South University, Changsha 410008, China
National International Joint Research Center for Medical Metabolomics, Changsha 410008, China
National Clinical Medical Research Center for Geriatric Diseases, Xiangya Hospital of Central South University, Changsha 410008, China
Organ Fibrosis Key Laboratory of Hunan Province, Central South University, Changsha 410008, China | xuhuiye@csu.edu.cn | | Chinese Cohort Study of Chronic Kidney Disease Group | | |
|
| Hits: 338 |
| Download times: 113 |
| Abstract: |
| 目的 分析24 h尿钙排泄量与慢性肾脏病（CKD）严重程度及预后的相关性。方法 选择中国慢性肾脏病队列研究中3 375例的CKD 1~4期（18~74岁）的参与者为研究对象，采用Kaplan-Meier生存模型和Cox比例风险回归模型等进行时间-事件分析，以探索24 h尿钙排泄量与终末期肾脏病（ESKD）、心血管疾病（CVD）和全因死亡事件发生率之间的关联性。结果 在4.17（3.37，5.20）年的随访时间内，24 h尿钙排泄量<0.60、0.60~、1.20~、≥2.32 mmol组中分别有179、145、104和38例发展为ESKD。与24 h尿钙排泄量<0.60 mmol相比，高水平尿钙排泄量（1.20~、≥2.32 mmol）与CKD患者较低的ESKD事件发生风险相关，HR值（95%CI）分别为0.71（0.54~0.93）和0.43（0.29~0.64）。24 h尿钙排泄量与CVD和全因死亡事件终点无统计学关联。结论 在CKD患者中，24 h尿钙排泄量与CKD患者ESKD事件的发生风险相关。 |
| English Abstract: |
| Objective To analyze the relationship between 24-hour urinary calcium (24 h UCa) level and the risk of end-stage kidney disease (ESKD), cardiovascular disease (CVD), and all-cause mortality. Methods In the Chinese Cohort Study of Chronic Kidney Disease, we examined 3 375 patients aged 18-74 years with CKD stages 1-4. Kaplan-Meier survival and Cox proportional hazard regression models were used to test a time-to-event association between levels of 24 h UCa and incidence of ESKD, CVD, and all-cause mortality. Results During a follow-up of 4.17 (3.37, 5.20) years, 179, 145, 104 and 38 ESKD events occurred in <0.60, 0.60-, 1.20-, ≥2.32 mmol 24 h UCa groups. Higher levels of 24 h UCa (1.20-,≥2.32 mmol) were independently associated with a lower incidence of ESKD events in patients with CKD, with HR (95%CI) of 0.71 (0.54-0.93) and 0.43 (0.29-0.64), respectively. No significant associations with CVD and all-cause mortality endpoints were detected. Conclusion Among patients with CKD, levels of 24 h UCa displayed an association with the risk of ESKD among patients with CKD stages 1-4. |
|
View Fulltext
Html FullText
View/Add Comment Download reader |
| Close |
|
|
|